MeiraGTx Financial Ratios
NASDAQ: MGTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
10.69+0.19 (+1.81%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MeiraGTx ratio analysis
MeiraGTx earned a net margin of -140.3% in FY 2025, up from -444.1% a year earlier. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
MeiraGTx financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 7.72 | 13.47 | 28.29 | 18.50 | 27.79 | 36.70 | 48.92 | — | — |
| Price / book | — | 6.61 | 2.87 | 2.50 | 5.65 | 2.39 | 3.41 | 2.45 | — |
| Operating margin | -130.2% | -493.4% | -977.8% | -730.9% | -193.0% | -401.9% | -438.4% | — | — |
| Net margin | -140.3% | -444.1% | -599.5% | -814.2% | -211.0% | -372.6% | -411.9% | — | — |
| Free cash flow margin | -61.7% | -328.9% | -895.6% | -741.6% | -150.9% | -545.5% | 83.2% | — | — |
| Return on equity (ROE) | — | -217.9% | -60.8% | -110.1% | -42.9% | -24.3% | -28.7% | -102.2% | — |
| Return on assets (ROA) | -46.7% | -54.8% | -25.7% | -40.7% | -24.9% | -15.9% | -16.9% | -85.5% | -120.1% |
| Debt / equity | — | 1.08 | 0.52 | 0.60 | 0.01 | — | — | — | — |
| Current ratio | 0.75 | 2.03 | 2.38 | 1.88 | 2.69 | 5.03 | 5.47 | 4.82 | 0.54 |
| Revenue growth | 144.6% | 137.4% | -12.0% | -57.8% | 142.2% | 17.1% | — | — | — |